Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Longer-Term Efficacy and Safety of Zodasiran in Patients with Mixed Hyperlipidaemia.
Journal: European journal of preventive cardiology
Published: May 11, 2026
Use of plozasiran across a spectrum of hypertriglyceridemia: Long-term efficacy and safety data from the open-label extension period of SHASTA-2 and MUIR Trials.
Journal: American journal of preventive cardiology
Published: February 16, 2026
Genetic modelling of triglyceride-rich lipoprotein/remnant lowering mimics APOC3-silencing and predicts clinically relevant coronary heart disease event reductions.
Journal: European journal of preventive cardiology
Published: July 08, 2025
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial.
Journal: The lancet. Diabetes & endocrinology
Published: July 02, 2025
Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia.
Journal: Journal of the American College of Cardiology
Published: February 13, 2025
Temporal Effects of Plozasiran on Lipids and Lipoproteins in Persistent Chylomicronemia.
Journal: Circulation
Published: November 16, 2024
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk.
Journal: The New England journal of medicine
Published: September 03, 2024
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia.
Journal: The New England journal of medicine
Published: May 29, 2024
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia.
Journal: The New England journal of medicine
Published: May 28, 2024
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial.
Journal: JAMA cardiology
Published: April 07, 2024
Pharmacokinetics, Pharmacodynamics, and Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label Study.
Journal: Clinical therapeutics
Published: March 30, 2022
Evaluation of the Pharmacokinetics and Safety of AMG 986 Tablet and Capsule Formulations in Healthy Adult Subjects: A Phase I, Open-Label, Randomized Study.
Journal: Drugs in R&D
Published: March 14, 2022
Last Updated: 09/26/2026